These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26926468)

  • 41. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents.
    Alam MM; Hassan AHE; Kwon YH; Lee HJ; Kim NY; Min KH; Lee SY; Kim DH; Lee YS
    Arch Pharm Res; 2018 Jan; 41(1):35-45. PubMed ID: 29094267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polypharmacology-based ceritinib repurposing using integrated functional proteomics.
    Kuenzi BM; Remsing Rix LL; Stewart PA; Fang B; Kinose F; Bryant AT; Boyle TA; Koomen JM; Haura EB; Rix U
    Nat Chem Biol; 2017 Dec; 13(12):1222-1231. PubMed ID: 28991240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
    Jänne PA; Kim G; Shaw AT; Sridhara R; Pazdur R; McKee AE
    Clin Cancer Res; 2016 Jun; 22(11):2613-7. PubMed ID: 27250931
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current situation and future usage of anticancer drug databases.
    Wang H; Yin Y; Wang P; Xiong C; Huang L; Li S; Li X; Fu L
    Apoptosis; 2016 Jul; 21(7):778-94. PubMed ID: 27193464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Computational polypharmacology analysis of the heat shock protein 90 interactome.
    Anighoro A; Stumpfe D; Heikamp K; Beebe K; Neckers LM; Bajorath J; Rastelli G
    J Chem Inf Model; 2015 Mar; 55(3):676-86. PubMed ID: 25686391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histone deacetylase inhibitors in cancer therapy.
    Lee MJ; Kim YS; Kummar S; Giaccone G; Trepel JB
    Curr Opin Oncol; 2008 Nov; 20(6):639-49. PubMed ID: 18841045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selection of protein conformations for structure-based polypharmacology studies.
    Pinzi L; Caporuscio F; Rastelli G
    Drug Discov Today; 2018 Nov; 23(11):1889-1896. PubMed ID: 30099123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
    Adhikari N; Amin SA; Jha T
    Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules.
    Dutta D; Das R; Mandal C; Mandal C
    J Chem Inf Model; 2018 Jan; 58(1):68-89. PubMed ID: 29243930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
    Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
    Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
    Hameed R; Khan A; Khan S; Perveen S
    Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.
    Marks PA
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1049-66. PubMed ID: 20687783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update of new small-molecule anticancer drugs approved from 2015 to 2020.
    Liang X; Wu P; Yang Q; Xie Y; He C; Yin L; Yin Z; Yue G; Zou Y; Li L; Song X; Lv C; Zhang W; Jing B
    Eur J Med Chem; 2021 Aug; 220():113473. PubMed ID: 33906047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
    Martínez-Iglesias O; Ruiz-Llorente L; Sánchez-Martínez R; García L; Zambrano A; Aranda A
    Clin Transl Oncol; 2008 Jul; 10(7):395-8. PubMed ID: 18628067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current status of development of anticancer agents in Japan.
    Morita T; Hori A; Narimatatsu H; Tanimoto T; Kami M
    Int J Hematol; 2008 Jun; 87(5):484-489. PubMed ID: 18443741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.